Slide 1: Q2 & H1 2026 Financial Results
Q2 & H1 2026 Financial Results Conference call | August 27, 2026 www.materialise.com | NASDAQ & EURONEXT: MTLS
Slide 2: Safe Harbor Summary
Safe Harbor Summary This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, our intentions, beliefs, assumptions, projections,
Slide 3: Agenda
Agenda • Q2 2026 Business Highlights • Q2 2026 Financial Highlights Brigitte de Vet-Veithen CEO • Q2 & H1 2026 Financial Results • 2026 Financial Guidance • Q&A Koen Berges CFO 3
Slide 4: Q2 2026 Business Update
Q2 2026 Business Update H1 report published • To be consulted on our Investor Relations website • In compliance with Euronext requirements Strengthening Executive Committee • CHRO: Annelies Missotten • CDIO: Philippe Verlinde • EVP Medical Koen Peters leaving the company 30 year anniversary of Mater
Slide 5: Q2 2026 Business Update
Q2 2026 Business Update Medical – Making the Exceptional Accessible • Hospital Forum reflects continued maturation of the personalized care market • Investment in Replasia expands Materialise’s personalized hip care portfolio • Materialise offers complete minimally invasive MIOS workflow Software –
Slide 6: Q2 2026 – Financial Highlights
Q2 2026 – Financial Highlights • Revenue of 70.1 mEUR, representing an increase of 8.1% from Q2 2025 • Gross Profit of 39.8 mEUR, representing 56.8% of revenue • Adjusted EBIT of 3.9 mEUR, representing 5.5% of revenue • Net profit of 3.3 mEUR, representing 6 EUR-ct. per share • Net Cash position of
Slide 7: Consolidated Revenue
Q2 & Half-Year 2026 Consolidated Revenue +3.9% Q2 2026 Revenue by Segment 131,210 136,349 14% Software Medical +8.1% 34% Manufacturing 70,073 64,831 53% Q2 2025 Q2 2026 HY 2025 HY 2026 [Data in kEUR unless notes otherwise. All numbers and percentages rounded] • Quarterly revenue of 70.1 mEUR, repres
Slide 8: Consolidated Adjusted EBITDA & EBIT
Q2 & Half-Year 2026 Consolidated Adjusted EBITDA & EBIT +22.2% +71.5% 17,642 6,351 14,434 4.7% 12.9% +26.9% +15.7% 11.0% 3,880 3,703 9,593 8,288 3,058 5.5% 2.8% 13.7% 4.7% 12.8% Q2 2025 Q2 2026 HY 2025 HY 2026 Q2 2025 Q2 2026 HY 2025 HY 2026 Adj. EBITDA Adj. EBIT [Data in kEUR unless noted otherwise
Slide 9: Medical Segment
Q2 & Half-Year 2026 Medical Segment +9.6% +5.1% 70,039 20,787 19,775 63,928 29.7% 30.9% +7.7% +12.2% 36,873 11,553 10,728 32,850 32.7% 31.3% Q2 2025 Q2 2026 HY 2025 HY 2026 Q2 2025 Q2 2026 HY 2025 HY 2026 Revenue Adj. EBITDA [Data in kEUR unless noted otherwise. All numbers and perc entages rounded]
Slide 10: Software Segment
Q2 & Half-Year 2026 Software Segment -2.1% +6.7% 19,647 19,242 2,103 1,971 10.9% -28.6% 1,373 10.0% -2.7% 9,872 9,601 981 13.9% 10.2% Q2 2025 Q2 2026 HY 2025 HY 2026 Q2 2025 Q2 2026 HY 2025 HY 2026 Revenue Adj. EBITDA [Data in kEUR unless noted otherwise. All numbers and perc entages rounded] • Q2 2
Slide 11: Manufacturing Segment
Q2 & Half-Year 2026 Manufacturing Segment -1.2% 47,635 47,067 -4 -1.2% -0.0% -285 +6.7% 22,109 23,597 -3.6% -807 -2.5% Q2 2025 Q2 2026 HY 2025 HY 2026 Q2 2025 Q2 2026 -1,185 HY 2025 HY 2026 Revenue Adj. EBITDA [Data in kEUR unless noted otherwise. All numbers and perc entages rounded] • Q2 2026 reve
Slide 12: Income Statement Highlights
Income Statement Highlights Q2 Half-Year Gross profit margin (in %) (in thousands of euros, except where indicated) 2026 2025 2026 2025 58.3% Revenue 70,073 64,831 136,349 131,210 56.8% 56.8% 57.0% Cost of sales (30,297) (27,053) (58,679) (56,708) Gross profit 39,776 37,778 77,670 74,502 Research &
Slide 13: Other Financial Highlights
Other Financial Highlights Balance Sheet items 30/06/26 12/31/25 Cash flow from operations (in thousands of euros, except where indicated) 15,060 Cash and equivalents 133,735 133,918 9,686 Borrowings 59,521 63,113 8,146 Net Cash 74,214 70,805 27 Trade receivables 56,173 54,938 Q2 2025 Q2 2026 HY 202
Slide 14: 2026 Financial Guidance
2026 Financial Guidance We maintain our previous revenue guidance but increase our Adjusted EBIT guidance based on solid H1 results • Expect 2026 consolidated revenue within 273 - 283 mEUR range • Expect 2026 consolidated Adjusted EBIT within 12 - 14 mEUR range, revised upwards from our previous ran
Slide 15: Adjusted EBIT/EBITDA Reconciliation
Appendix Adjusted EBIT/EBITDA Reconciliation Q2 Half-Year [Data in kEUR unless noted otherwise. All numbers and perc entages rounded] 2026 2025 2026 2025 Net profit/(loss) 3,331 199 5,152 (337) Income taxes (304) (521) 358 (287) Financial expenses 871 4,039 1,571 6,811 Financial income (1,113) (987)
Slide 16: Thank You
Thank You Contact: Investor Relations Materialise investors@materialise.com 16